The Valencia, Calif.-based firm did not disclose the share price. Based on the closing stock price Tuesday, the offering could raise about $60 million, though it's likely the deal will be priced at a discount to that $8.13 close. Wall Street apparently thought so, too, sending shares (NASDAQ:MNKD) down 68 cents, or 8.4 percent, to close Wednesday at $7.45. (BioWorld Today) Read More
